Marcy l’Étoile (France) – bioMérieux, a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary specialized in molecular syndromic infectious disease testing, has received U.S. Food and Drug Administration (FDA) De Novo authorization for the BIOFIRE® RP2.1 Panel.
Canada
All news
MNA Rizqy and Minister Fitzgibbon honor the employees of bioMérieux Canada Inc. with the National Assembly Medal for their exceptional contribution during the COVID-19 pandemic
27 June, 2022The bioMérieux Canada team remained true to its commitment towards public health by ensuring the installation of the BIOFIRE® systems in record time. The team traveled across Canada despite the sanitary restrictions to ensure adequate user training and was able to demonstrate agility and innovation...
bioMérieux – 2020 Financial Results
24 February, 2021
bioMérieux announces the expansion of the CE marking of its molecular biology ARGENE® SARS-CoV-2 diagnostic test to include saliva specimens.
17 November, 2020
Marcy l’Etoile, France – November 16, 2020 – bioMérieux, a world leader in the field of in vitro diagnostics, has announced the expansion of its ARGENE® range for the detection of SARS-CoV-2. As a complement to nasopharyngeal swab specimens, the singleplex SARS-CoV-2 R-GENE® real-time PCR test may now be used on saliva and oropharyngeal (throat) swab specimens for the detection of the virus that causes COVID-19. This development helps optimize laboratory workflows.
First-Half 2020 Results
02 September, 2020
Second-Quarter 2020 Business Performance Preannouncement
15 July, 2020
First-Quarter 2020 Business Review
24 March, 2020